Lineage Cell Therapeutics Stock Price Prediction

LCTX Stock  USD 0.50  0.10  16.67%   
At this time, The RSI of Lineage Cell's share price is at 59. This indicates that the stock is in nutural position, most likellhy at or near its resistance level. The main idea of RSI analysis is to track how fast people are buying or selling Lineage Cell, making its price go up or down.

Oversold Vs Overbought

59

 
Oversold
 
Overbought
The successful prediction of Lineage Cell's future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Lineage Cell Therapeutics, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Lineage Cell's stock price prediction:
EPS Estimate Next Quarter
(0.04)
EPS Estimate Current Year
(0.11)
EPS Estimate Next Year
(0.09)
Wall Street Target Price
4.5714
EPS Estimate Current Quarter
(0.03)
Using Lineage Cell hype-based prediction, you can estimate the value of Lineage Cell Therapeutics from the perspective of Lineage Cell response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Lineage Cell to buy its stock at a price that has no basis in reality. In that case, they are not buying Lineage because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Lineage Cell after-hype prediction price

    
  USD 0.51  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Lineage Cell Basic Forecasting Models to cross-verify your projections.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lineage Cell's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
0.091.757.10
Details
Naive
Forecast
LowNextHigh
0.010.355.69
Details
7 Analysts
Consensus
LowTargetHigh
5.015.506.11
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.03-0.03-0.03
Details

Lineage Cell After-Hype Price Prediction Density Analysis

As far as predicting the price of Lineage Cell at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Lineage Cell or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Lineage Cell, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Lineage Cell Estimiated After-Hype Price Volatility

In the context of predicting Lineage Cell's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Lineage Cell's historical news coverage. Lineage Cell's after-hype downside and upside margins for the prediction period are 0.03 and 5.86, respectively. We have considered Lineage Cell's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
0.50
0.51
After-hype Price
5.86
Upside
Lineage Cell is dangerous at this time. Analysis and calculation of next after-hype price of Lineage Cell Therapeutics is based on 3 months time horizon.

Lineage Cell Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Lineage Cell is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lineage Cell backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Lineage Cell, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.77 
5.35
  0.01 
  0.03 
5 Events / Month
14 Events / Month
In about 5 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
0.50
0.51
2.00 
53,500  
Notes

Lineage Cell Hype Timeline

Lineage Cell Therapeutics is now traded for 0.50. The entity has historical hype elasticity of 0.01, and average elasticity to hype of competition of 0.03. Lineage is anticipated to increase in value after the next headline, with the price projected to jump to 0.51 or above. The average volatility of media hype impact on the company the price is over 100%. The price jump on the next news is forecasted to be 2.0%, whereas the daily expected return is now at -0.77%. The volatility of related hype on Lineage Cell is about 12260.42%, with the expected price after the next announcement by competition of 0.53. The company reported the previous year's revenue of 8.95 M. Net Loss for the year was (21.49 M) with profit before overhead, payroll, taxes, and interest of 13.97 M. Given the investment horizon of 90 days the next anticipated press release will be in about 5 days.
Check out Lineage Cell Basic Forecasting Models to cross-verify your projections.

Lineage Cell Related Hype Analysis

Having access to credible news sources related to Lineage Cell's direct competition is more important than ever and may enhance your ability to predict Lineage Cell's future price movements. Getting to know how Lineage Cell's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Lineage Cell may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
MAIAMAIA Biotechnology 0.22 6 per month 0.00 (0.11) 8.37 (9.23) 28.10 
ARMPArmata Pharmaceuticals(0.23)4 per month 3.71  0  7.14 (7.05) 33.83 
FREQFrequency Therapeutics(0.02)2 per month 3.90  0.06  5.71 (6.15) 90.18 
PRTGPortage Biotech(0.03)2 per month 9.06  0.10  15.56 (14.59) 154.25 
AGEAgeX Therapeutics 0.00 0 per month 4.99  0.06  8.20 (9.20) 47.55 
CVKDCadrenal Therapeutics, Common(0.11)11 per month 6.02  0.17  17.85 (7.47) 47.47 
ICCCImmuCell(0.12)6 per month 2.33 (0.02) 3.40 (3.29) 21.64 
ONTTFOxford Nanopore Technologies 0.00 0 per month 4.03  0.04  11.11 (7.58) 21.94 
REPLReplimune Group(0.10)7 per month 2.86  0.11  7.38 (5.60) 15.63 
NVCTNuvectis Pharma 1.21 10 per month 0.00 (0.03) 10.84 (10.50) 75.91 
LYRALyra Therapeutics 0.01 4 per month 0.00 (0.10) 8.00 (10.00) 41.07 
KRONKronos Bio(0.05)10 per month 0.00 (0.06) 5.56 (6.25) 16.20 
GOSSGossamer Bio 0.00 7 per month 0.00 (0.13) 6.06 (4.76) 17.73 
NLTXNeoleukin Therapeutics(0.14)1 per month 0.00 (0.08) 4.05 (3.53) 27.84 
NUVBNuvation Bio 0.21 8 per month 4.59 (0) 9.48 (8.36) 21.30 
OVIDOvid Therapeutics 0.03 7 per month 0.00 (0.07) 5.93 (6.25) 19.20 
NXTCNextCure 0.01 5 per month 0.00 (0.14) 5.22 (6.37) 21.68 
CNTBConnect Biopharma Holdings 0.02 5 per month 5.38  0.01  12.12 (9.01) 48.67 
SPROSpero Therapeutics 0.01 9 per month 0.00 (0.13) 3.79 (4.58) 14.92 
BOLTBolt Biotherapeutics 0.03 8 per month 0.00 (0.15) 4.76 (4.48) 14.96 
CHRSCoherus BioSciences 0.01 9 per month 0.00 (0.04) 7.62 (6.94) 34.15 
GRCLGracell Biotechnologies 0.00 0 per month 6.35  0.16  16.34 (6.25) 52.11 

Lineage Cell Additional Predictive Modules

Most predictive techniques to examine Lineage price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Lineage using various technical indicators. When you analyze Lineage charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Lineage Cell Predictive Indicators

The successful prediction of Lineage Cell stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Lineage Cell Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Lineage Cell based on analysis of Lineage Cell hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Lineage Cell's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Lineage Cell's related companies.
 2023 2024 (projected)
Dividend Yield0.0016160.001535
Price To Sales Ratio21.0419.99

Story Coverage note for Lineage Cell

The number of cover stories for Lineage Cell depends on current market conditions and Lineage Cell's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Lineage Cell is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Lineage Cell's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Lineage Cell Short Properties

Lineage Cell's future price predictability will typically decrease when Lineage Cell's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Lineage Cell Therapeutics often depends not only on the future outlook of the potential Lineage Cell's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Lineage Cell's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding172.7 M
Cash And Short Term Investments35.5 M

Additional Tools for Lineage Stock Analysis

When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.